Student or educator? Sign up with your school email and get 6 months of Pro free.

The DOI matches its Crossref record; 44 of the 44 references it cites were found in a registry or an index; 1 of the 4 sources its claims cite were checked for support.

Comparative effectiveness of GLP-1 receptor agonists on glycaemic control, body weight, and lipid profile for type 2 diabetes: systematic review and network meta-analysis

Open access

Abstract

Abstract Objective To evaluate the comparative efficacy and safety of glucagon-like peptide-1 receptor agonists (GLP-1RAs) on glycaemic control, body weight, and lipid profile in adults with type 2 diabetes. Design Systematic review and network meta-analysis. Data sources PubMed, Web of Science, Cochrane Central Register of Controlled Trials (CENTRAL), and Embase from database inception to 19 August 2023. Eligibility criteria for selecting studies Eligible randomised controlled trials enrolled adults with type 2 diabetes who received GLP-1RA treatments and compared effects with placebo or any GLP-1RA drug, with a follow-up duration of at least 12 weeks. Trials with a crossover design, non-inferiority studies comparing GLP-1RA and other drug classes without a placebo group, using withdrawn drugs, and non-English studies were deemed ineligible. Results 76 eligible trials involving 15 GLP-1RA drugs and 39 246 participants were included in this network meta-analysis; all subsequent estimates refer to the comparison with placebo. All 15 GLP-1RAs effectively lowered haemoglobin A 1c and fasting plasma glucose concentrations. Tirzepatide induced the largest reduction of haemoglobin A 1c concentrations (mean difference −2.10% (95% confidence interval −2.47% to −1.74%), surface under the cumulative ranking curve 94.2%; high confidence of evidence), and fasting plasma glucose concentrations (−3.12 mmol/L (−3.59 to −2.66), 97.2%; high confidence), and proved the most effective GLP-1RA drug for glycaemic control. Furthermore, GLP-1RAs were shown to have strong benefits to weight management for patients with type 2 diabetes. CagriSema (semaglutide with cagrilintide) resulted in the highest weight loss (mean difference −14.03 kg (95% confidence interval −17.05 to −11.00); high confidence of evidence), followed by tirzepatide (−8.47 kg (−9.68 to −7.26); high confidence). Semaglutide was effective in lowering the concentration of low density lipoprotein (−0.16 mmol/L (−0.30 to −0.02)) and total cholesterol (−0.48 mmol/L (−0.84 to −0.11)). Moreover, this study also raises awareness of gastrointestinal adverse events induced by GLP-1RAs, and concerns about safety are especially warranted for high dose administration. Conclusions GLP-1RAs are efficacious in treating adults with type 2 diabetes. Compared with the placebo, tirzepatide was the most effective GLP-1RA drug for glycaemic control by reducing haemoglobin A 1c and fasting plasma glucose concentrations. GLP-1RAs also significantly improved weight management for type 2 diabetes, with CagriSema performing the best for weight loss. The results prompt safety concerns for GLP-1RAs, especially with high dose administration, regarding gastrointestinal adverse events. Systematic review registration PROSPERO CRD42022342845.

Overview

CoChat Summary

## TL;DR

This systematic review and network meta-analysis of 76 randomized controlled trials (39,246 participants) compared 15 GLP-1 receptor agonists for type 2 diabetes. Tirzepatide ranked best for glycaemic control, CagriSema for weight loss, and several drugs increased gastrointestinal adverse events.

## Key findings

  • Across 76 trials involving 39,246 adults, all 15 GLP-1RAs significantly reduced HbA1c and fasting plasma glucose versus placebo.
  • Tirzepatide had the largest HbA1c reduction: mean difference −2.10% (95% CI −2.47% to −1.74%) and fasting plasma glucose reduction: −3.12 mmol/L (−3.59 to −2.66), both with high confidence of evidence.
  • CagriSema produced the greatest weight loss: −14.03 kg (95% CI −17.05 to −11.00); tirzepatide was next: −8.47 kg (−9.68 to −7.26).
  • Semaglutide lowered low-density lipoprotein by −0.16 mmol/L (−0.30 to −0.02) and total cholesterol by −0.48 mmol/L (−0.84 to −0.11); PEG-loxenatide increased HDL by 0.16 mmol/L (0.00 to 0.31).

## Methods

  • Systematic review and network meta-analysis of randomized controlled trials, registered in PROSPERO (CRD42022342845) and reported under PRISMA/PRISMA-NMA.
  • Searched PubMed, Web of Science, CENTRAL, and Embase from inception to 19 August 2023, plus conference websites, ClinicalTrials.gov, references, and prior reviews; included English-language peer-reviewed RCTs in adults with type 2 diabetes, follow-up ≥12 weeks.
  • Used frequentist random-effects network meta-analysis in Stata, with SUCRA rankings, node-splitting/design-treatment interaction for consistency, CINeMA and RoB 2 for evidence quality/bias, and meta-regression/subgroup analyses by dose, follow-up, age, diabetes duration, and background treatment.

## Limitations

  • The paper states that included trials varied in population characteristics and follow-up durations, which may have led to imprecise effect estimates.
  • The paper states that participants had little control over diet and exercise, which may have influenced blood glucose and body weight.
  • The paper states that some trials did not provide enough information to assess randomization, allocation concealment, or blinding, and some drugs had few studies, so subgroup and comparative results should be interpreted cautiously.
  • Evident from the text: the review excluded non-English studies, conference abstracts, crossover trials, and non-inferiority studies without a placebo arm, so the evidence base may be narrower than all available GLP-1RA trials.

Model-written summary. Check it against the paper before relying on it.

Integrity signals

Registry

Crossref · 10.1136/bmj-2023-076410

Cites

44 of 44 references verified0 citation errors · 0 not checkable

Statistics

Nothing to recompute.

Figures

Image 1
CC BY-NC · PubMed Central
Fig 1 Flow diagram of preferred reporting items identified, included, and excluded for systematic reviews and meta-analyses (PRISMA)
Fig 1 Flow diagram of preferred reporting items identified, included, and excluded for systematic reviews and meta-analyses (PRISMA)CC BY-NC · PubMed Central
Fig 2 Network of available comparisons of GLP-1RAs and placebo for HbA1c. The size of the nodes is proportional to the number of trial participants, and the thickness of the line connecting the nodes is proportional to the randomised number of trial participants directly comparing the two treatments. Numbers represent the number of trials contributing to each treatment comparison. GLP-1RA=glucagon-like peptide 1 receptor agonist; PEG-loxenatide=polyethylene glycol loxenatide; ITCA 650=a combination of drug and device containing exenatide in osmotic mini pump
Fig 2 Network of available comparisons of GLP-1RAs and placebo for HbA1c. The size of the nodes is proportional to the number of trial participants, and the thickness of the line connecting the nodes is proportional to the randomised number of trial participants directly comparing the two treatments. Numbers represent the number of trials contributing to each treatment comparison. GLP-1RA=glucagon-like peptide 1 receptor agonist; PEG-loxenatide=polyethylene glycol loxenatide; ITCA 650=a combination of drug and device containing exenatide in osmotic mini pumpCC BY-NC · PubMed Central
Fig 3 Forest plot of network effect sizes between GLP-1RAs and placebo for HbA1c measured in percentage. According to the network confidence meta-analysis (CINeMA) framework, the certainty of evidence is visually represented in the forest map, with varying colours indicating different confidence levels. The complete CINeMA assessments are shown in appendix 9. GLP-1RA=glucagon-like peptide-1 receptor agonist; PEG-loxenatide=polyethylene glycol loxenatide; ITCA 650=a combination of drug and device containing exenatide in osmotic mini pump
Fig 3 Forest plot of network effect sizes between GLP-1RAs and placebo for HbA1c measured in percentage. According to the network confidence meta-analysis (CINeMA) framework, the certainty of evidence is visually represented in the forest map, with varying colours indicating different confidence levels. The complete CINeMA assessments are shown in appendix 9. GLP-1RA=glucagon-like peptide-1 receptor agonist; PEG-loxenatide=polyethylene glycol loxenatide; ITCA 650=a combination of drug and device containing exenatide in osmotic mini pumpCC BY-NC · PubMed Central
Fig 4 Network of available comparisons between GLP-1RAs and placebo for fasting blood glucose. The size of the nodes is proportional to the number of trial participants, and the thickness of the line connecting the nodes is proportional to the randomised number of trial participants directly comparing the two treatments. Numbers represent the number of trials contributing to each treatment comparison. GLP-1RA=glucagon-like peptide 1 receptor agonist; PEG-loxenatide=polyethylene glycol loxenatide
Fig 4 Network of available comparisons between GLP-1RAs and placebo for fasting blood glucose. The size of the nodes is proportional to the number of trial participants, and the thickness of the line connecting the nodes is proportional to the randomised number of trial participants directly comparing the two treatments. Numbers represent the number of trials contributing to each treatment comparison. GLP-1RA=glucagon-like peptide 1 receptor agonist; PEG-loxenatide=polyethylene glycol loxenatideCC BY-NC · PubMed Central
Fig 5 Forest plot of network effect sizes between GLP-1RAs and placebo for fasting blood glucose. Certainty of evidence is visually represented in the forest map, with varying colours indicating different confidence levels. The complete CINeMA assessments are shown in appendix 9. GLP-1RA=glucagon-like peptide 1 receptor agonist; PEG-loxenatide=polyethylene glycol loxenatide
Fig 5 Forest plot of network effect sizes between GLP-1RAs and placebo for fasting blood glucose. Certainty of evidence is visually represented in the forest map, with varying colours indicating different confidence levels. The complete CINeMA assessments are shown in appendix 9. GLP-1RA=glucagon-like peptide 1 receptor agonist; PEG-loxenatide=polyethylene glycol loxenatideCC BY-NC · PubMed Central
Fig 6 Network of available comparisons between GLP-1RAs and placebo for weight loss. The size of the nodes is proportional to the number of trial participants, and the thickness of the line connecting the nodes is proportional to the randomised number of trial participants directly comparing the two treatments. Numbers represent the number of trials contributing to each treatment comparison. GLP-1RA=glucagon-like peptide-1 receptor agonist; PEG-loxenatide=polyethylene glycol loxenatide; ITCA 650=a combination of drug and device containing exenatide in osmotic mini pump
Fig 6 Network of available comparisons between GLP-1RAs and placebo for weight loss. The size of the nodes is proportional to the number of trial participants, and the thickness of the line connecting the nodes is proportional to the randomised number of trial participants directly comparing the two treatments. Numbers represent the number of trials contributing to each treatment comparison. GLP-1RA=glucagon-like peptide-1 receptor agonist; PEG-loxenatide=polyethylene glycol loxenatide; ITCA 650=a combination of drug and device containing exenatide in osmotic mini pumpCC BY-NC · PubMed Central
Fig 7 Forest plot of network effect sizes between GLP-1RAs and placebo for weight loss. Certainty of evidence is visually represented in the forest map, with varying colours indicating different confidence levels. The complete CINeMA assessments are shown in appendix 9. GLP-1RA=glucagon-like peptide-1 receptor agonist; PEG-loxenatide=polyethylene glycol loxenatide; ITCA 650=a combination of drug and device containing exenatide in osmotic mini pump
Fig 7 Forest plot of network effect sizes between GLP-1RAs and placebo for weight loss. Certainty of evidence is visually represented in the forest map, with varying colours indicating different confidence levels. The complete CINeMA assessments are shown in appendix 9. GLP-1RA=glucagon-like peptide-1 receptor agonist; PEG-loxenatide=polyethylene glycol loxenatide; ITCA 650=a combination of drug and device containing exenatide in osmotic mini pumpCC BY-NC · PubMed Central
Fig 8 Estimates in network meta-analysis for common adverse events of glucagon-like peptide-1 receptor agonist compared with placebo. (A) discontinuation; (B) diarrhoea; (C) nausea; (D) vomiting. Effect sizes are presented as odds ratios with 95% confidence intervals (CIs). PEG=polyethylene glycol
Fig 8 Estimates in network meta-analysis for common adverse events of glucagon-like peptide-1 receptor agonist compared with placebo. (A) discontinuation; (B) diarrhoea; (C) nausea; (D) vomiting. Effect sizes are presented as odds ratios with 95% confidence intervals (CIs). PEG=polyethylene glycolCC BY-NC · PubMed Central

Verification

Claims the paper makes

1 Valid · 0 Not valid · 1 Not checked · 41 Own results and interpretations

23 more claims

Create a free account to see all 43 claims and every source verdict.

See all claims — free account
  • It may state two separate claims as one. 13
  • Probably not a substantial claim. 5

Create a free account to see these claims.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

7 more claims about this paper

Create a free account to see every claim other papers make about this one.

See all claims — free account

Citations

Cites

Show all 42 references

Cited by

See all 558

Metadata

Authors
Yao, H., Zhang, A., Li, D., Wu, Y., Wang, C.-Z., Wan, J.-Y., & Yuan, C.-S.
Affiliations
  • Beijing University of Chinese Medicine (CN)
  • University of Chicago (US)
Venue
BMJ
Publisher
BMJ
Published
2024-01-29
Volume
384
Pages
e076410
ISSN
1756-1833 (ISSN-L)
OpenAlex
W4391309422
Cited by
558
References
42
Citations by year
2026: 196 · 2025: 259 · 2024: 103
FWCI
32.55
Type
journal article
Language
en
Open access
Locations
  • BMJ (publishedVersion, cc-by-nc)
  • PubMed Central (publishedVersion, cc-by-nc)
  • PubMed (publishedVersion)
  • HighWire Press Open Archive (submittedVersion)
Funders
  • National Natural Science Foundation of China (82274379)
  • Beijing University of Chinese Medicine
  • Fundamental Research Funds for the Central Universities
Topics
  • Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Treatment and Management
  • Health Sciences › Medicine › Pharmacology (medical) › Pharmacology and Obesity Treatment
  • Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Management and Research
Keywords
GLP-1 receptor agonists, type 2 diabetes, glycemic control, weight loss, lipid profile, HbA1c, fasting blood glucose, tirzepatide, semaglutide, cagrilintide, LDL cholesterol, triglycerides, drug safety, drug efficacy comparison, weight management
MeSH terms
Glycemic Control, Glucagon-Like Peptide-1 Receptor Agonists, Adult, Blood Glucose, Body Weight, Diabetes Mellitus, Type 2, Glycated Hemoglobin, Humans, Hypoglycemic Agents, Weight Loss, Lipid Metabolism

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

A language model drew the claims from the paper on 2026-10-10, under version 3 of the claim definition (model deepseek-v4.1-flash, prompt extract-v3).

A second model labelled each claim on 2026-10-10 (model jev-1.13-20260917, definition revision gold-guideline-v0.2).

Cited sources are checked with a language model’s help (gpt-6-sol).

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Comparative effectiveness of GLP-1 receptor agonists on glycaemic control, body weight, and lipid profile for type 2 diabetes: systematic review and network meta-analysis. https://app.cochat.ai/papers/10.1136/bmj-2023-076410
The paper
Yao, H., Zhang, A., Li, D., Wu, Y., Wang, C.-Z., Wan, J.-Y., & Yuan, C.-S. (2024). Comparative effectiveness of GLP-1 receptor agonists on glycaemic control, body weight, and lipid profile for type 2 diabetes: systematic review and network meta-analysis. BMJ. https://doi.org/10.1136/bmj-2023-076410

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.